ASY202

COMBINATION_PRODUCT2 trials

Sponsors

Aspeya, Inc.

Conditions

MigraineSafety in Asthma Patients

Phase 1

Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma

RecruitingNCT07665892

Aspeya, Inc.Safety in Asthma Patients

Start: 2026-05-26End: 2027-03-01Target: 40Updated: 2026-09-02

Phase 2

Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients

RecruitingNCT07646613

Aspeya, Inc.Migraine

Start: 2026-05-19End: 2027-03-01Target: 108Updated: 2026-09-02